Business Context and Reporting Period
Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 31, 2001
Business Overview: The Company is a biopharmaceutical firm focused on developing stem and progenitor cell therapies for degenerative diseases (e.g., Parkinson's, Alzheimer's, liver failure, diabetes). In 1999, the Company restructured to abandon its former Encapsulated Cell Therapy (ECT) program to concentrate exclusively on stem cell technology. As of the reporting date, the Company has no commercial products and relies on external financing and grants.
Key Financial Metrics
| Metric (in thousands) | 2001 | 2000 | 1999 |
|---|---|---|---|
| Total Revenue | $805 | $74 | $5,022 |
| Research & Development Expenses | $8,603 | $5,979 | $9,984 |
| General & Administrative Expenses | $3,788 | $3,361 | $4,927 |
| Net Loss | $(3,446) | $(11,125) | $(15,709) |
| Net Loss Per Share (Basic/Diluted) | $(0.19) | $(0.58) | $(0.84) |
| Cash and Cash Equivalents (Year End) | $13,697 | $6,069 | $4,760 |
| Long-term Debt & Capital Leases | $2,316 | $2,605 | $2,937 |
| Stockholders' Equity | $13,208 | $21,699 | $3,506 |
Note: Revenue in 2001 consisted of $505,000 in NIH grants and $300,000 from the assignment of technology rights. The 2001 net loss was significantly reduced by a $7.8 million gain on the sale of Modex Therapeutics shares.
Material Changes vs. Prior Period
- Revenue: Increased from $74,000 in 2000 to $805,000 in 2001, driven by the receipt of NIH grants and the sale of retained rights to former ECT technology. This contrasts with 1999, where revenue was $5.0 million primarily from an AstraZeneca collaboration that was terminated in 1999.
- Operating Expenses: R&D expenses increased 44% to $8.6 million due to facility expansion in Palo Alto and increased personnel to advance neural and liver stem cell programs. G&A expenses rose 13% to $3.8 million.
- Net Loss: The net loss narrowed significantly to $3.4 million from $11.1 million in 2000. This improvement was primarily due to a one-time realized gain of $7.8 million from the sale of Modex Therapeutics stock, offsetting higher operating costs.
- Liquidity: Cash and cash equivalents more than doubled to $13.7 million, bolstered by equity financings (including a $4.0 million drawdown on an equity line and a $5.0 million preferred stock issuance) and the Modex sale proceeds.
Outlook, Risks, and Management Commentary
- Outlook: Management expects to incur substantial operating losses in the future. The Company estimates its existing capital resources will fund operations through December 2002. No product revenues are expected for several years.
- Financing Needs: The Company is dependent on external financing (equity/debt), grants, and potential corporate partnerships. It has an equity line of credit with Sativum Investments Limited for up to $30 million.
- Real Estate Contingency: The Company faces ongoing costs related to its former Rhode Island facilities (approx. $1.0 million for 2002). It is actively seeking to sublease, assign, or sell these properties; failure to do so could materially adversely affect liquidity.
- Risks: Key risks include the failure to obtain corporate partners, delays in clinical testing, regulatory hurdles (FDA approval for cell therapies), and the uncertainty of patent protection against third-party claims.
- Unusual Items: The 2001 financials include a $7.8 million gain on the sale of Modex shares and a $744,000 deemed dividend related to convertible preferred stock accretion.
Investor Verification Checklist
- Cash Runway: Verify if the $13.7 million cash balance is sufficient to sustain operations through the projected December 2002 date, considering the $1.0 million annual cost for Rhode Island facilities.
- Real Estate Disposal: Confirm the status of subleasing or selling the Rhode Island pilot manufacturing and headquarters facilities to mitigate ongoing lease obligations.
- Financing Terms: Review the terms of the 3% Cumulative Convertible Preferred Stock issued to Riverview Group (Millennium Partners), specifically the mandatory redemption date (Dec 4, 2003) and conversion price ($2.00).
- Grant Sustainability: Assess the reliability of NIH grant funding ($300k/year and $225k/year) as a revenue source, noting these are subject to satisfactory progress and fund availability.
- Intellectual Property: Evaluate the strength of the patent portfolio (30 issued US patents) against potential third-party infringement claims in the competitive stem cell field.